Everolimus Exposure and Early Metabolic Response as Predictors of Treatment Outcomes in Breast Cancer Patients Treated with Everolimus and Exemestane

Author(s):: Willemsen, A.E.C.A.B.; Geus-Oei, L.F. de; Boer, M. de; Tol, J.; Kamm, Y.; Jong, P.C. de; Jonker, M.A.; Vos, A.H.; Grootjans, W.; Groot, J.W.B. de; Mulder, S.F.; Aarntzen, E.H.J.G.; Gerritsen, W.R.; Herpen, C.M.L. van; Erp, N.P. van

Published: 2018
Publication type: Article / Letter to editor

Date issued: 2018-10-31
Language: English
Is part of: Targeted Oncology (2018), Vol. 13, no. 5, p. 641-648
hdl: 1887/78877
doi: 10.1007/s11523-018-0596-8
URL: https://link.springer.com/article/10.1007/s11523-018-0596-8